FYERS
Home
/
Stocks
/
Profit Loss
/
CORONA Remedies Profit & Loss

CORONA Remedies Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
₹422 Cr₹353 Cr₹342 Cr₹361 Cr₹347 Cr₹294 Cr₹298 Cr₹314 Cr
₹3 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹76 L₹2 Cr
₹426 Cr₹357 Cr₹345 Cr₹363 Cr₹349 Cr₹295 Cr₹298 Cr₹316 Cr
₹343 Cr₹301 Cr₹269 Cr₹292 Cr₹286 Cr₹250 Cr₹238 Cr₹256 Cr
₹96 Cr₹66 Cr₹85 Cr₹81 Cr₹72 Cr₹56 Cr₹70 Cr₹69 Cr
₹3 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹80 Cr₹54 Cr₹55 Cr₹70 Cr₹61 Cr₹43 Cr₹58 Cr₹57 Cr
₹60 Cr₹45 Cr₹41 Cr₹52 Cr₹46 Cr₹31 Cr₹45 Cr₹43 Cr

Share Price Live Stats

Open (₹)2,024.00
Volume (₹)9,627.00
High (₹)2,067.00
Upper Circuit2,431.40
Low (₹)2,020.10
Lower Circuit1,621.00
Prev Close2,026.20
52W High (₹)2,292.40
Price2,058.00
52W Low (₹)1,336.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)12376.70 Cr
Div. Yield (%)0.49
PE Ratio62.18
Debt to Equity0.19
Price to Book12.74
Book Value122.12
EPS (TTM)32.54
Face Value10.00
ROE (%)27.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
CORONANSE
LTP
1W Low
1W High
Market cap (₹)
1746.4-13.6 (-0.77%)
1725.50
1776.60
4,24,466Cr
9023-317 (-3.39%)
8937.50
9431.50
2,46,222Cr
4580-76.9 (-1.65%)
4551.80
4682
1,76,301Cr
1124.7+7.2 (0.64%)
1107.30
1150.90
1,12,818Cr
2036.9+0.3 (0.01%)
2007.80
2069.20
1,10,823Cr
1314.6+13.6 (1.05%)
1300.20
1333.30
1,07,447Cr
1216+19 (1.59%)
1196.90
1250.70
1,03,471Cr
2335-33.5 (-1.41%)
2317.50
2426.80
97,850Cr
1662.9-30.1 (-1.78%)
1654.10
1715
96,836Cr
1953.2-3.3 (-0.17%)
1925.70
1964.90
89,629Cr
2058+34 (1.68%)
1941.50
2067
12,377Cr

Key Highlights of CORONA Remedies Ltd’s P&L

In 2026-03-31, CORONA Remedies Ltd reported total revenue of ₹1413.83Cr, compared with ₹1202.35Cr in 2025-03-31, reflecting CORONA Remedies Ltd turnover.

Depreciation was ₹37.87Cr and finance costs were ₹6.97Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹240.42Cr in 2026-03-31 as compared to ₹198.53Cr in 2025-03-31.

Net Profit (PAT) was ₹185.12Cr in 2026-03-31 compared with ₹149.43Cr in 2025-03-31.

Earnings per share (EPS) were ₹30.27 in 2026-03-31, compared with ₹24.43 in 2025-03-31.